Japan Antiarrhythmic Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Sodium Channel Blockers, Beta Blockers, Potassium Channel Blockers, Calcium Channel Blockers, and Other), By Route of Administration (Oral, Parenteral, and Other), and Japan Antiarrhythmic Drugs Market Insights, Industry Trend, Forecasts to 2035

Japan Antiarrhythmic Drugs Market Insights Forecasts to 2035

• The Japan Antiarrhythmic Drugs Market Size Was Estimated at USD 65.3 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 7.43% from 2025 to 2035
• The Japan Antiarrhythmic Drugs Market Size is Expected to Reach USD 143.7 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Antiarrhythmic Drugs Market Size is anticipated to reach USD 143.7 Million by 2035, growing at a CAGR of 7.43% from 2025 to 2035. The Japan antiarrhythmic drugs market is driven by various factors, including the rising incidence of cardiovascular disorders, innovation in drug development, the need for effective arrhythmia therapies, the rising elderly population, and rising health awareness.

Market Overview

Antiarrhythmic drugs are medications designed to treat irregular heart rhythms. The Japan antiarrhythmic drugs market focuses on research, development, and sale of the medication which helps to treat irregular heart rhythms and helps to maintain regular cardiac functions. This medication acts by changing the electrical impulse of the heart, thus regulating rhythm disturbances, like atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular arrhythmias. These drugs include various classes such as sodium channel blockers, beta blockers, potassium channel blockers, and calcium channel blockers. They are administered through oral and parenteral routes. Japan's antiarrhythmic drugs market is experiencing steady growth due to the country's aging population. The aging population is more susceptible to the risk of arrhythmic conditions such as atrial fibrillation, which raises the demand for antiarrhythmic drugs. The rising demand for personalized medicines is the key trend in this market.

Report Coverage

This research report categorizes the market for the Japan antiarrhythmic drugs market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan antiarrhythmic drugs market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan antiarrhythmic drugs market.

Driving Factors

The rise in cardiovascular diseases, such as coronary artery disease, cerebrovascular disease, peripheral artery disease, rheumatic heart disease, congenital heart disease, and deep vein thrombosis/pulmonary embolism, raises the demand for antiarrhythmic drugs. The government is highly investing in healthcare systems to enhance diagnostic and treatment options for cardiovascular diseases also contributes to the market growth. Additionally, increased accessibility, innovation in diagnostic technology, and awareness campaigns play a crucial role in market growth.

Restraining Factors

One of the significant restraints is side effects associated with arrhythmic drugs, such as dizziness, nausea, cardiovascular toxicity, and GI symptoms limit the market expansion. The new advanced drugs are expensive, which further limits the market.

Market Segmentation

The Japan antiarrhythmic drugs market share is classified into drug class and route of administration.

• The beta blockers segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.   

The Japan antiarrhythmic drugs market is segmented by drug class into sodium channel blockers, beta blockers, potassium channel blockers, calcium channel blockers, and other. Among these, the beta blockers segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segmental growth is attributed to its efficacy in reducing heart rate and controlling blood pressure. Additionally, they lower the risk of stroke and cardiovascular diseases.

• The oral segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.  

The Japan antiarrhythmic drugs market is segmented by route of administration into oral, parenteral, and other. Among these, the oral segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is because they are self-administered by patients and reduce hospital visits. Most of the antiarrhythmic drugs are taken by mouth over a long period for lasting treatment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan antiarrhythmic drugs market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer
• Novartis
• Eisai Co., Ltd.
• Daiichi Sankyo Co., Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Nippon Shinyaku Co., Ltd.
• Other

Recent Developments

• In September 2024, Boston Scientific received Japanese regulatory approval for the FARAPULSE Pulsed Field Ablation System. FARAPULSE PFA System, which is used for the isolation of pulmonary veins for the treatment of paroxysmal atrial fibrillation.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan antiarrhythmic drugs market based on the below-mentioned segments:

Japan Antiarrhythmic Drugs Market, By Drug Class

• Sodium Channel Blockers
• Beta Blockers
• Potassium Channel Blockers
• Calcium Channel Blockers
• Other

Japan Antiarrhythmic Drugs Market, By Route of Administration

• Oral
• Parenteral
• Other